Literature DB >> 12077779

Hepatocyte growth factor pretreatment reduces apoptosis and mucosal damage after intestinal ischemia-reperfusion.

Keith A Kuenzler1, Philip Y Pearson, Marshall Z Schwartz.   

Abstract

BACKGROUND/
PURPOSE: Ischemia-reperfusion (IR) injury to the intestine can result in mucosal damage and cellular death. This study was designed to evaluate the protective effects of pretreatment with hepatocyte growth factor (HGF) on intestine after moderate IR injury.
METHODS: Control animals (n = 7) received 48 hours of intravenous saline, and treatment animals (n = 7) received HGF (150 microg/kg/d). After 35 minutes of mesenteric artery occlusion and 120 minutes of reperfusion, serum and jejunal mucosa samples were obtained. Fluorometric assays were performed for hexosaminidase A (HEX A) and beta-glucuronidase (GLUC), enzyme markers of enterocyte necrosis. Apoptosis was quantified by the TUNEL method. Transcription of tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) was assessed by multiplex reverse transcription polymerase chain reaction (RT-PCR) Statistical analysis was performed using the Student's t test.
RESULTS: After HGF pretreatment, HEX A and GLUC activities were reduced from 543 +/- 28 to 343 +/- 35 nmole/h/mL (P <.01) and 183 +/- 29 to 119 +/- 22 nmole/h/mL (P <.01), respectively. Pretreated animals had a reduced number of apoptotic cells per 10 crypts (33 +/- 11) compared with untreated rats (225 +/- 24) after IR injury (P <.01). Mean IFN-gamma band intensity was lower in HGF-pretreated animals (0.05 +/- 0.02) compared with controls (0.31 +/- 0.09; P <.05).
CONCLUSIONS: Pretreatment with HGF reduces the severe crypt apoptosis and cellular necrosis after IR injury to the intestine. These data suggest that HGF may be beneficial in attenuating IR damage and thus may have significant clinical application. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12077779     DOI: 10.1053/jpsu.2002.33884

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  9 in total

Review 1.  Can we protect the gut in critical illness? The role of growth factors and other novel approaches.

Authors:  Jessica A Dominguez; Craig M Coopersmith
Journal:  Crit Care Clin       Date:  2010-07       Impact factor: 3.598

2.  Effects of hepatocyte growth factor on rat inflammatory bowel disease models.

Authors:  Yoshio Ohda; Kazutoshi Hori; Toshihiko Tomita; Nobuyuki Hida; Tadashi Kosaka; Yoshihiro Fukuda; Hiroto Miwa; Takayuki Matsumoto
Journal:  Dig Dis Sci       Date:  2005-05       Impact factor: 3.199

Review 3.  Ischemia-reperfusion injury of the intestine and protective strategies against injury.

Authors:  Ismail Hameed Mallick; Wenxuan Yang; Marc C Winslet; Alexander M Seifalian
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

Review 4.  The role of growth factors in intestinal regeneration and repair in necrotizing enterocolitis.

Authors:  Kathryn J Rowland; Pamela M Choi; Brad W Warner
Journal:  Semin Pediatr Surg       Date:  2013-05       Impact factor: 2.754

5.  c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells.

Authors:  E Gregory MacEwen; Jon Kutzke; Jennifer Carew; Josep Pastor; Julie A Schmidt; Rachel Tsan; Douglas H Thamm; Robert Radinsky
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

6.  Hepatocyte growth factor ameliorates inflammatory bowel disease in a rat model.

Authors:  L Grier Arthur; Keith A Kuenzler; Marshall Z Schwartz
Journal:  J Gastrointest Surg       Date:  2003-12       Impact factor: 3.267

7.  The canonical Notch signaling was involved in the regulation of intestinal epithelial cells apoptosis after intestinal ischemia/reperfusion injury.

Authors:  Guoqing Chen; Zhicao Zhang; Yingdong Cheng; Weidong Xiao; Yuan Qiu; Min Yu; Lihua Sun; Wensheng Wang; Guangsheng Du; Yingchao Gu; Ke Peng; Chao Xu; Hua Yang
Journal:  Int J Mol Sci       Date:  2014-05-06       Impact factor: 5.923

8.  Hepatocyte growth factor, hepatocyte growth factor activator and arginine in a rat fulminant colitis model.

Authors:  Nathan P Zwintscher; Puja M Shah; Shashikumar K Salgar; Christopher R Newton; Justin A Maykel; Ahmed Samy; Murad Jabir; Scott R Steele
Journal:  Ann Med Surg (Lond)       Date:  2016-04-05

9.  Skeletal muscle targeting in vivo electroporation-mediated HGF gene therapy of bleomycin-induced pulmonary fibrosis in mice.

Authors:  Yukio Umeda; Tsutomu Marui; Yukihiro Matsuno; Koyo Shirahashi; Hisashi Iwata; Hisato Takagi; Kunio Matsumoto; Toshikazu Nakamura; Atsushi Kosugi; Yoshio Mori; Hirofumi Takemura
Journal:  Lab Invest       Date:  2004-07       Impact factor: 5.662

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.